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In multicellular organisms, cell size is tightly cont-
rolled by nutrients and growth factors. Increasing
ambient glucose induces enhancedprotein synthesis
and cell size. Continued exposure of cells to high
glucose in vivo, as apparent under pathological
conditions, results in cell hypertrophy and tissue
damage. We demonstrate that activation of TGF-b
signaling has a central role in glucose-induced cell
hypertrophy in fibroblasts and epithelial cells. Block-
ing the kinase activity of the TbRI receptor or loss of
its expression prevented the effects of high glucose
on protein synthesis and cell size. Exposure of cells
to high glucose induced a rapid increase in cell
surface levels of the TbRI and TbRII receptors and
a rapid activation of TGF-b ligand by matrix metallo-
proteinases, including MMP-2 and MMP-9. The
consequent autocrine TGF-b signaling in response
to glucose led to Akt-TOR pathway activation.
Accordingly, preventing MMP-2/MMP-9 or TGF-
b-induced TOR activation inhibited high glucose-
induced cell hypertrophy.
INTRODUCTION
Cell size is highly controlled, and its deregulation has been impli-
cated in obesity, diabetes, and cancer. Cell growth is defined as
increase in cell mass, often associated with increased protein
synthesis (Mamane et al., 2006). The best characterized
signaling pathway that regulates cell size is defined by the
sequential activation of phosphatidylinositol 3-kinase (PI3K),
Akt, TOR, and S6 kinase. Growth factors that act through tyro-
sine kinase receptors, such as insulin and IGF-1, activate PI3K,
thus enhancing the phosphorylation of Akt. Consequent activa-
tion of mTOR results in phosphorylation of S6 kinase and 4E-
BP1, leading to enhanced translation (Hay and Sonenberg,
2004;Manning andCantley, 2007). The contribution of additional
signaling pathways that control cell size during homeostasis
remains poorly understood.
Glucose is an essential nutrient for cells and provides energy
for cell growth. After being transported into the cell by glucose
transporters, glucose undergoes a metabolic process known
as glycolysis, which generates ATP and NADPH as an energy
source and regulates the activity of TOR, protein synthesis,and cell size (Herman and Kahn, 2006). High glucose induces
increased protein synthesis and cell size and promotes cell
hypertrophy in various tissues and organs, including muscle,
kidney, and heart. Elevated levels of blood glucose, i.e., hyper-
glycemia, consequently increase the risk and complications of
diseases such as obesity, diabetes, and heart disease (Wolf
and Ziyadeh, 1999; Sartorelli and Fulco, 2004; Neubauer,
2007). How glucose induces increased cell size is poorly under-
stood. Increased Akt activity has been shown to stimulate trans-
port and metabolism of glucose and triggers TOR-dependent
increases in protein translation (Plas and Thompson, 2005;
Manning and Cantley, 2007).
Several observations correlate hyperglycemia to increased
activity of transforming growth factor-b (TGF-b). In diabetic
patients and rodent models of diabetes, continuous exposure
of cells to high glucose has been linked to hypertrophy of prox-
imal tubular and mesangial cells and accumulation of extracel-
lular matrix proteins and fibrosis (Ziyadeh, 2004). Consistent
with the induction of extracellular matrix protein expression by
TGF-b and with TGF-b’s role in fibrosis (Zavadil and Bo¨ttinger,
2005), TGF-b1 levels were increased in the glomerular and
tubular compartments of the kidney in rodent models of dia-
betes, and Smad3 activation was observed in these cells
(Kolm-Litty et al., 1998; Hong et al., 2001; Isono et al., 2002).
High glucose was also shown to induce TGF-b expression,
leading to production of extracellular matrix proteins (Ziyadeh
et al., 1994), and exposure of cells to high glucose can increase
the expression of TGF-b1 and/or the TbRII receptor (Hong et al.,
2001; Iglesias-de la Cruz et al., 2002). These observations
suggest a functional linkage of glucose-stimulated increase of
protein synthesis, in particular of extracellular matrix proteins,
with increased TGF-b signaling. However, a direct role of
TGF-b signaling in the glucose-stimulated increase in cell size
has not been revealed.
TGF-b, the prototype of a 33-member TGF-b family, acts
through cell surface receptor complexes of two type I and two
type II receptors, i.e., TbRI and TbRII. Following ligand binding,
the TbRII receptors phosphorylate and activate the TbRI recep-
tors, which C-terminally phosphorylate and thereby activate
Smad2 and Smad3. These then form a complex with Smad4,
translocate into the nucleus, and regulate the transcription of
TGF-b-responsive genes (Shi and Massague, 2003; Feng and
Derynck, 2005). Smad signaling does not account for other
TGF-b responses and, accordingly, non-Smad mechanisms
that relay TGF-b signals have been characterized (Derynck and
Zhang, 2003; Moustakas and Heldin, 2005). Recent findings re-
vealed that TGF-b can activate PI3K, leading to activation of theDevelopmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 35
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Glucose Increases Cell Size through TGF-b SignalingPI3K-Akt-TOR-S6 kinase pathway in response to TGF-b. Activa-
tion of this pathway by TGF-b was observed in cells undergoing
epithelial-to-mesenchymal transition and allows TGF-b to
directly regulate translation, complementing the Smad-medi-
ated transcription regulation, and to enhance cell size (Lamouille
and Derynck, 2007; Das et al., 2008).
We explored the physiological connection between the effects
of glucose on cell metabolism and TGF-b signaling, based on our
observation that TGF-b can induce increased cell size through
activation of Akt-TOR signaling (Lamouille and Derynck, 2007).
We found that, in fibroblasts and epithelial cells, glucose-
induced increase in cell size was blocked by inhibiting the func-
tion of the TbRI kinase, thus blocking TGF-b signaling. Glucose
induced a rapid externalization of the TbRII and TbRI receptors
at the cell surface and metalloproteinase-mediated TGF-b acti-
vation, thus strongly enhancing autocrine TGF-b signaling,
and, in turn, activating the Akt-TOR pathway. Consequently,
high glucose-induced cell hypertrophy was also inhibited by pre-
venting matrix metalloproteinase-2/9 activation or TGF-b-
induced TOR activation. These observations have relevance
for the physiology of hyperglycemia-induced pathologies that
are associated with tissue hypertrophy, including cancer.
RESULTS
Glucose Increases Cell Size and Protein Content
To evaluate the effect of glucose, we analyzed cells by flow cy-
tometry using forward light scatter as a parameter indicative of
cell size. Since cell size varies with changes in the cell cycle
(Coelho and Leevers, 2000; Pyronnet and Sonenberg, 2001),
we examined the size of only the cells in the G1 phase, although
the effects of glucose on the cell cycle were minor (data not
shown). Mouse embryonic fibroblasts (MEFs) and rat kidney
epithelial NRK-52E cells were cultured overnight without glucose
and then exposed tomediumcontaining 4mM (normal) or 25mM
(high) glucose. In these cells, 4 mM glucose induced a 3%–10%
increase in cell size, and 25 mM glucose induced an increase in
cell size of 20%–50% after 24 hr (Figures 1A and 1B). Cells
cultured in 4 mM glucose underwent a 5%–20% increase in cell
size following exposure to 25 mM glucose after 24 hr (Figures
1C and 1D). The increase in cell size induced by 25 mM glucose
was reversible uponwithdrawal of glucose or a decrease to 4mM
glucose (see Figures S1A–S1D available online). As osmolarity
control, 25 mM mannose (Tesfamariam et al., 1990) did not
increase cell size (Figure S1E). Similarly to MEFs and NRK-52E
cells, a shift from 4 mM to 25 mM glucose induced an increase
in cell size of human umbilical vein endothelial cells, T4-2 breast
carcinoma cells, and HepG2 hepatoma cells (Figure S2).
Because increased cell size often correlates with increased
protein content, we measured the protein content in untreated
and glucose-treated cells. Glucose increased the cell protein
content by 60%–90% in MEFs and 100%–170% in NRK-52E
cells after 24 hr (Figure 1E). Accordingly, glucose induced
increased protein synthesis, measured by incorporation of
3H-labeled leucine into newly synthesized proteins (Figure 1F).
Similarly to MEFs and NRK-52E cells, glucose induced an
increase in cell size and protein content in HepG2 carcinoma
cells (data not shown). These results indicate that glucose can
stimulate increase of protein synthesis and cell size.36 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.TGF-b Receptor Activity Is Required for
Glucose-Induced Increase of Cell Size
TGF-b induces increased cell size and protein content in cells
undergoing epithelial-to-mesenchymal transition (Lamouille
and Derynck, 2007). Since the TbRI receptor activates TGF-
b-induced transcription and translation responses, we exam-
ined the effect of glucose in TbRI/ MEFs. In contrast to
wild-type MEFs (Figure 1A), glucose did not significantly
increase the size of the TbRI/ MEFs (Figure 2A, top).
However, ectopic expression of TbRI in the TbRI/ MEFs
restored the glucose-induced increase in cell size (Figure 2A,
bottom, and Figure 2B). We also knocked down the expression
of TbRI in MEFs using siRNA for mouse TbRI, which resulted in
an 80% decrease in TbRI mRNA level (Figure 2C) and nearly
complete downregulation of TGF-b-induced expression of the
TGF-b-responsive Smad7 gene (data not shown). Downregula-
tion of TbRI expression blocked the glucose-induced increase
of protein content (Figure 2D) and cell size (Figure 2E) in
MEFs. We obtained similar results in HepG2 cells using siRNA
for human TbRI (data not shown). We conclude that the
glucose-induced increase of cell size and protein content
requires TbRI.
To examine the role of the TbRI kinase in the glucose-
induced increase in cell size and protein content, we treated
the MEFs and NRK-52E cells with the kinase inhibitor
SB431542, which specifically targets the TbRI receptor (Inman
et al., 2002). SB431542 inhibited the glucose-induced increase
of cell size (Figures 2F and 2G) and protein synthesis (Figures
2H and 2I) in both cell types and HepG2 cells (data not shown).
The cells in the presence of SB431542 were slightly smaller
than those in the absence of SB431542, suggesting a contribu-
tion of autocrine TGF-b signaling to cell size (Figures 2F and
2G). Similar observations were made in human umbilical vein
endothelial cells, T42 breast cancer cells, and HepG2 hepa-
toma cells (Figure S2). These data indicate that the TbRI kinase
is essential for the regulation of protein synthesis and cell size
by glucose.
TGF-bSignaling IncreasesCell Size and Protein Content
in Glucose-Responsive Cells
To evaluate whether TGF-b signaling leads to increased cell size
in glucose-responsive cells, we treated the MEFs with TGF-b,
which had only a minor effect on the cell cycle (data not shown).
TGF-b induced an increase in cell size (Figure 3A) and protein
content (Figure 3B) of wild-type MEFs in G1 phase. In contrast,
TGF-b did not affect the cell size of TbRI/ MEFs (Figure 3A),
but ectopic TbRI expression resulted in increased cell size and
restored the stimulatory effect of TGF-b on cell size (Figure 3C).
Conversely, inhibition of autocrine TGF-b signaling with
SB431542 resulted in decreased protein content and cell size
(Figures 3B and 3D). In addition, expression of a mutant TbRI
(caTbRI) that activates TGF-b signaling independent of ligand
led to increased cell size in TbRI/ MEFs (Figure 3E). These
data indicate that, in these cells, TGF-b signaling leads to
increased cell size and protein synthesis. Together with our
previous data, we conclude that the glucose-induced increase
in cell size and protein synthesis requires functional TGF-b
signaling and that activation of TGF-b signaling may mediate
the glucose-induced cell size and protein synthesis.
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Glucose Increases Cell Size through TGF-b SignalingGlucose Induces Smad3 Activation and Signaling
The requirement of TbRI signaling for glucose-induced increase
in cell size and protein synthesis raises the possibility that
glucose may activate TGF-b signaling. As shown in Figures 4A
and 4B, shifting the cells from no or 4 mM glucose to 25 mM
glucose induced a rapid C-terminal phosphorylation of Smad3,
similarly to Smad3 activation in response to TGF-b. Similarly to
the effect of glucose on cell size, SB431542 blocked the activa-
tion of Smad3 by glucose, decreasing it to a level below the one
in the presence of 4 mM glucose (Figures 4A and 4B). The rapid
activation of Smad3 by glucose suggested that this response
does not require new protein synthesis. Accordingly, C-terminal
phosphorylation of Smad3 in response to glucose occurred in
the presence of the protein synthesis inhibitor cycloheximide
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Figure 1. Glucose Induces Increase in Cell
Size and Protein Synthesis
(A and B) MEFs (A) and NRK-52E cells (B) were
cultured without glucose for 24 hr and shifted to
medium containing 0, 4, or 25 mM glucose for
24 hr. Cells in G1 phase were analyzed by flow
cytometry using the forward light scatter (FSC)
parameter, and relative cell size distribution was
determined.
(C and D) FSC profiles of MEFs (C) and NRK-52E
cells (D) cultured with 4 mM glucose and then
shifted to medium with 4 or 25 mM glucose. The
FSC profiles of cells in G1 were obtained as in A
and B.
(E) Protein content of MEFs or NRK-52E cells in
G1, cultured without glucose for 24 hr and then
shifted to medium without or with 25 mM glucose
for 24 hr.
(F) New protein synthesis in MEFs or NRK-52E
cells cultured without glucose for 24 hr and then
shifted to medium without or with 25 mM glucose
for 24 hr. Values were normalized for cell number,
relative to untreated cells.
One out of two experiments is shown with SD for
triplicates.
(Figure 4C). The increase in Smad3 acti-
vation in response to 25 mM glucose
was still apparent after 24 hr and was
reversed upon withdrawal of glucose or
a decrease to 4mM glucose (Figure S1F).
Upon activation by TbRI, Smad2 and
-3 undergo nuclear translocation. As
shown in Figure 4D, glucose induced nu-
clear translocation of Smad2/3, similarly
to TGF-b. The glucose-induced nuclear
translocation of Smad2 and Smad3 was
blocked by SB431542 (Figure 4D), indi-
cating that it required the TbRI kinase
activity.
Finally, we evaluated whether glucose
activated the transcription activity of
Smad3. As shown in Figure 4E, glucose
enhanced the transcription from the
Smad3-responsive 4xSBE-lux promoter
(Liberati et al., 2001) in MEFs and NRK-
52E cells, indicating increasedSmad3 activity. SB431542blocked
the glucose-induced transcription and decreased the basal
activity in this assay, an indication of autocrine TGF-b signaling
under basal conditions and an essential role of TbRI activity in
this response to glucose. These data demonstrate that glucose
activates signaling by TbRI, resulting in Smad3 activation and
Smad3-mediated transcription in the absence of added TGF-b.
Glucose Enhances TGF-b/Smad Signaling
Since glucose activates TGF-b signaling, the response to
exogenous TGF-b may depend on the level of glucose in the
cell culture medium. We examined the effect of glucose on
transcription from the Smad3-dependent 4xSBE-lux promoter.
Glucose enhanced the basal transcription, which depends onDevelopmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 37
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Figure 2. Glucose-Induced Increase in Cell Size and Protein Content Requires TbRI Kinase
(A) Cell size distribution of TbRI/ MEFs and TbRI/ MEFs expressing a reintroduced TbRI (TbRI/ MEFs + TbRI), cultured without or with 25 mM glucose for
24 hr. Only cells in G1 phase were analyzed.
(B) FSC profiles of wild-type (WT) MEFs and TbRI/MEFs + TbRI in G1, cultured without or with 25mM glucose for 24 hr. The relative mean values with SD (error
bars) for five replicates are shown as a bar graph.
(C) MEFs were transfected with TbRI siRNA or control siRNA (Ctrl). TbRI mRNA was quantified using qRT-PCR.
(D) MEFs, cotransfected with green fluorescent siRNA and control or TbRI siRNA, were cultured without or with 25 mM glucose for 24 hr. The protein content of
green fluorescent cells in G1 phase was measured.
(E) Cell size distribution of MEFs in G1, transfected with siRNA and cultured as in D, determined using the FSC parameter.
(F andG) Cell size distribution ofMEFs (F) or NRK-52E cells (G) in G1, cultured with 4 or 25mMglucose for 24 hr in the absence or presence of SB431542. The gray
lines, marked ‘‘Control 4 mM glucose,’’ in the lower panels correspond to the 4 mM glucose profiles in the absence of SB431542 that are shown in the upper
panels.38 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.
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Glucose Increases Cell Size through TGF-b Signalingautocrine TGF-b signaling, and the transcription response to
activated TbRI in NRK-52E cells and MEFs (Figures 5A and
5B). Glucose did not induce transcription from this reporter
in Smad3/ MEFs (Figure 5C), but expression of Smad3
restored the induction of 4xSBE-dependent transcription and
its increase by glucose (Figure 5C). Furthermore, the TGF-
b dose-dependent transcription from the Smad3-responsive
4xSBE promoter was substantially enhanced in the presence
of glucose (Figure 5D). Accordingly, glucose also enhanced
the expression of Smad7 mRNA in response to TGF-b (Fig-
ure 5E) without changing the time dependence of the
response (Figure 5F). Together, these results indicate that
glucose enhances the TGF-b-induced, Smad3-mediated tran-
scription activation.
Since TGF-b activates Akt-TOR signaling (Lamouille and
Derynck, 2007), we examined whether glucose also induces
(H) Protein content of MEFs or NRK-52E cells in G1, cultured without or with 25 mM glucose for 24 hr in the absence or presence of SB431542.
(I) New protein synthesis of MEFs or NRK-52E cells, cultured without or with 25 mM glucose for 24 hr in the absence or presence of SB431542. Values were
normalized to the cell number relative to untreated cells (*p < 0.01; **p > 0.05).
One out of two experiments is shown with SD for triplicates.
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Figure 3. TGF-b Induces Increases in Cell Size and
Protein Synthesis
(A) Cell size distribution of wild-type and TbRI/ MEFs in G1,
treated or not with TGF-b for 24 hr.
(B) Protein content of MEFs treated with TGF-b, SB431542, or
solvent control for 24 hr, normalized for cell number relative to
untreated cells (*p < 0.01).
(C) Cell size distribution of TbRI/ MEFs in G1, transfected
with a TbRI expression plasmid or control vector, and treated
or not with TGF-b for 24 hr.
(D) Cell size distribution of MEFs in G1, treated for 24 hr with
SB431542 or solvent control.
(E) Cell size distribution of TbRI/ MEFs in G1, transfected
with a plasmid encoding constitutively active (ca) TbRI or
control vector.
One out of two experiments is shown with SD for triplicates.
Akt activation in MEFs and NRK-52E cells. As
shown in Figure 5G, switching cells from 4 mM
glucose to 25 mM glucose induced a rapid
increase of Akt phosphorylation. Similarly to the
activation of Smad3, Akt phosphorylation in
response to high glucose was blocked by
SB431542, indicating that it resulted from activa-
tion of TGF-b signaling. Furthermore, rapamycin,
an inhibitor of TOR in TOR complex 1, prevented
the 25 mM glucose-induced increase of cell
size in both MEFs and NRK-52E cells (Figure 5H),
as well as in endothelial and cancer cells (Fig-
ure S2). As was seen in response to SB431542
(Figures 2F and 2G), the cells in the presence
of rapamycin were slightly smaller than those in
the absence of rapamycin (Figure 5H), suggest-
ing a contribution of autocrine TGF-b signaling
leading to TOR activation in the control of cell
size. These results indicate that glucose induces
activation of Akt through induction of TGF-
b signaling and that TGF-b-induced Akt-TOR
signaling plays an essential role in glucose-regulated cell
size.
Glucose Increases the Cell Surface Expression
of TGF-b Receptors
The activation of Smad3 by glucose, and the glucose-induced
increase in cell size and protein content, dependent upon TbRI,
may be explained by an upregulation of the TGF-b signaling
system. Since TGF-b signals through a complex of TbRII and
TbRI, we investigated whether glucose affected the expression
of either receptor. Glucose did not induce rapid changes of TbRII
or TbRI mRNA (data not shown) or protein (Figure 6A, lower
panels) levels in MEFs or NRK-52E cells. In contrast, it induced
a rapid and strong increase in cell surface levels of both TbRII
and TbRI, as assessed by cell surface protein biotin labeling
(Figure 6A, upper panels). In MEFs, the levels of cell surfaceDevelopmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 39
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Glucose Increases Cell Size through TGF-b SignalingTGF-b receptors were strongly increased after 15 min of glucose
addition and started to decline after 30min (Figure 6A, left, upper),
possibly due to endocytosis. In NRK-52E cells, glucose induced
a slower increase of the cell surface levels of TbRI and TbRII,
which was apparent after 15 min and more pronounced after 30
min (Figure 6A, right, upper). Glucose did not induce changes in
the cell surface levels of the EGF receptor or transferrin receptor
1 (Figure 6B), suggesting that the effect of glucose on cell surface
expression of the TGF-b receptors was specific.
Vesicular transport in the secretory pathway can be arrested
by incubating cells at 15C or 20C to block exit from the endo-
plasmic reticulum (ER) or trans-Golgi network (Milgram and
Mains, 1994; Saraste et al., 1986). Incubation of the MEFs at
20C strongly impaired the glucose-induced cell surface expres-
sion of both TbRI and TbRII; no increase in cell surface levels of
TbRI or TbRII was apparent at 15 min, and only a modest
increase was observed at 30 min (Figure 6B, upper panels). At
15C, which impairs protein transport from the ER to the Golgi,
A
D
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B Figure 4. Glucose Induces Smad Phosphor-
ylation and Nuclear Translocation
(A) MEFs, cultured for 24 hr without glucose, were
incubated for 30 min without or with 25 mM
glucose in the presence or absence of SB431542,
lysed, and assayed by western blotting for phos-
pho-Smad3 (pSmad3), Smad2/3, or a-tubulin.
(B) MEFs and NRK-52E cells, cultured with 4 mM
glucose, were incubated for 30 min with normal
(4 mM, N) or high (25 mM, H) glucose, with or
without SB431542, lysed, and immunoblotted for
pSmad3 and Smad3.
(C) MEFs, cultured for 24 hr without glucose, were
incubated for 30 min without or with 25 mM
glucose in the absence or presence of cyclohexi-
mide (CHX), lysed, and immunoblotted for
pSmad3, Smad3, or a-tubulin.
(D) MEFs were treated with 25 mM glucose, TGF-
b, or glucose and SB431542 for 30 min, and the
subcellular localization of Smad2/3 was visual-
ized. DAPI was used to stain the nuclei.
(E) Effect of 25 mM glucose in the absence or
presence of SB431542 on transcription from the
4xSBE-lux reporter, transfected into MEFs or
NRK-52E cells.
One out of two experiments is shown with SD for
triplicates.
the glucose-induced increase in TbRI
and TbRII levels was also inhibited
(Figure 6B, lower panels). These data
suggest that glucose rapidly enhances
cell surface expression of TbRI and TbRII
by stimulating their transport.
We also used brefeldin A (BFA) to block
protein transport from the ER to the Golgi.
BFAprevented the increaseof cell surface
TbRI and TbRII levels in response to
glucose (Figure 6D, right). In the absence
of glucose treatment (i.e., at 0 min), cell
surface levels of TGF-b receptors are
higher in BFA-treated cells (right) than in
thecontrol group (left). Thismaybedue toeffectsofBFAonendo-
cytosis (Uhlin-Hansen and Yanagishita, 1995). Together, these
data indicate that glucose stimulates the transport of TGF-b
receptors from intracellular compartments to the cell surface.
Glucose Increases the Activation of TGF-b
In addition to enhancing the cell surface levels of TGF-b recep-
tors, glucose may also regulate the TGF-b ligand. Glucose did
not affect the TGF-b1, TGF-b2, and TGF-b3 mRNA levels in
MEFs but moderately enhanced their levels in NRK-52E cells
(Figure 7A). We also determined the amount of active TGF-b
ligand in themedium using a reporter cell line, TMLC, that scores
TGF-b activity through induction of luciferase expression from an
integrated promoter segment (Abe et al., 1994). Conditioned
media of glucose-treated or untreated cells were assayed and
calibrated against a concentration curve of TGF-b1. As shown
in Figure 7B, glucose induced the rapid generation of active
TGF-b in MEFs, increasing the levels of active TGF-b 10-fold40 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.
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Glucose Increases Cell Size through TGF-b Signaling(from 38.8 ± 4.2 to 390.3 ± 50.0 pg/ml; n = 6, p < 0.05) at 15 min.
No further enhancement of active TGF-b generation was seen at
subsequent time points (Figure 7B).
Since TGF-b is secreted in a latent complex that requires acti-
vation to bind to the receptors (Annes et al., 2003), active TGF-b
may be generated from latent TGF-b without changes in TGF-b
levels, or through increased release of total TGF-b by the cells.
To distinguish between these possibilities, we converted all latent
TGF-b in the conditioned medium into active TGF-b using heat
treatment and measured the levels of TGF-b in the TMLC reporter
assay. As shown in Figure 7C, glucose did not enhance the total
amount of TGF-b in the medium. Comparison of the active
TGF-b levels without and after heat treatment revealed that a third
of the total TGF-b was activated in response to glucose. These
data indicate that glucose induced a rapid activation of latent
TGF-b, without an effect on the total level of secreted TGF-b in
MEFs. In NRK-52E cells, the active TGF-b ligand was barely
measurable without heat treatment, and the total amount of
secreted TGF-b, assessed after heat treatment, was moderately
enhanced by glucose after 1 hr (Figure 7D), consistent with the
increased TGF-b mRNA levels (Figure 7A).
ED
CA B
F
HG
Figure 5. Glucose Enhances TGF-b-
Induced Smad3 Activity and Akt/TOR Acti-
vation
(A and B) Effect of TGF-b in the absence or pres-
ence of 25 mM glucose on transcription from the
4xSBE-lux reporter in NRK-52E cells (A) or MEFs
(B).
(C) Effect of 25 mM glucose on transcription from
4xSBE-lux in Smad3/ MEFs transfected with
a Smad3 expression plasmid or control vector
(*p < 0.01; **p > 0.05).
(D and E) Effect of increasing concentrations of
TGF-b, in the absence or presence of 25 mM
glucose, on transcription from 4xSBE-lux (D) and
Smad7 mRNA expression, quantified by qRT-
PCR (E), in MEFs.
(F) Effect of TGF-b, added for different times in the
absence or presence of 25 mM glucose, on
Smad7 mRNA expression.
(G) MEFs and NRK-52E cells were cultured with
4 mM glucose and then shifted for 5 min to normal
(4 mM, N) or high (25 mM, H) glucose, with or
without SB431542, lysed, and immunoblotted for
phospho-Akt (pAkt) and total Akt.
(H) Cell size distribution of MEFs and NRK-52E
cells, cultured with 4 mM glucose and then shifted
to 4mM or 25mM glucose for 24 hr in the absence
or presence of rapamycin, was determined by flow
cytometry using FSC as parameter. The gray lines,
marked ‘‘Control 4 mM glucose,’’ in the right
panels correspond to the 4 mM glucose profiles
in the absence of rapamycin, shown in the left
panels.
One out of two experiments is shown with SD for
triplicates.
The rapid activation of TGF-b in
response to glucose suggested that no
new protein synthesis was required. To
test this, we treated MEFs with glucose
in the presence or absence of cycloheximide, added the condi-
tioned media to the TMLC cells, and measured the induction of
luciferasemRNA expression. As shown in Figure 7E, the presence
of cycloheximide did not affect the induction of luciferase mRNA.
These results indicate that TGF-b activation in response to
glucose does not require new protein synthesis and that the acti-
vation of the TGF-b-responsive reporter resulted from a direct
induction by TGF-b in the medium rather than from a component
that might induce TGF-b expression in the reporter cells.
Together, these data indicate that glucose induced a rapid activa-
tion of latent TGF-b, without the need for new protein synthesis.
Glucose Induces Metalloproteinase-Mediated
Activation of Latent TGF-b
Various mechanisms have been shown to result in activation
of latent TGF-b (Annes et al., 2003). Among these, matrix metal-
loproteinases, i.e., MMP-2, -3, -9, -13, and -14, have been impli-
cated in TGF-b activation (Maeda et al., 2002; D’Angelo et al.,
2001; Yu and Stamenkovic, 2000). Considering the rapid activa-
tion of TGF-b in response to glucose, we evaluated the role
of MMPs in the glucose-induced activation of TGF-b. TheDevelopmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 41
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Glucose Increases Cell Size through TGF-b Signalingbroad-spectrum MMP inhibitor GM6001 inhibited glucose-stim-
ulated phosphorylation of Smad3 in MEFs and NRK-52E cells
(Figure 8A), indicating that MMPs mediate the activation of
TGF-b signaling. We also examined the effect of MMP inhibitors
on glucose-induced activation of TGF-b using the TMLC reporter
assay. GM6001 inhibited TGF-b activation in MEFs in response
to glucose by90% (Figure 8B). Since increased MMP-2 and -9
expression and activity have been associated with effects of high
glucose in fibroblasts (Polhill et al., 2004; Lee et al., 2007), we
examined their roles in glucose-induced activation of TGF-b.
Treatment of MEFs with specific MMP-2, MMP-9, or MMP-2/9
inhibitors conferred a 60%–70% inhibition of TGF-b activation,
whereas inhibition of MMP-13 had no effect (Figure 8B). Further-
more, both MMP-2 and MMP-9 inhibitors blocked the activation
of Smad3 by glucose (Figure 8C). Thus, the activation of TGF-b in
response to glucose is largely due to metalloproteinase activa-
tion, primarily of the related MMP-2 and -9. We then examined
whether MMP-mediated activation of TGF-b plays a role in
glucose-induced increase of cell size. As shown in Figure 8D,
GM6001 abolished the effect of glucose on the increase of cell
size in NRK-52E cells. To confirm that MMP-2 and MMP-9
mediate the effect of glucose on TGF-b activation and cell size,
we silenced the expression of MMP-2 and MMP-9. Transfection
of NRK-52E cells with siRNA specific for MMP-2 or MMP-9 re-
sulted in a strongly decreased activation of TGF-b in response
to glucose (Figure 8E). Furthermore, downregulation of MMP-2
or MMP-9 expression blocked the high glucose-induced
increase of cell size in NRK-52E cells (Figure 8F) and endothelial
cells (Figure S3). In NRK-52E cells, MMP-9 siRNA conferred
C D
A B Figure 6. Glucose Increases the Cell
Surface Levels of TbRI and TbRII
(A) MEFs and NRK-52E cells were treated with
25 mM glucose for 15 or 30 min. Cell surface
proteins were labeled by biotinylation. Western
blotting of the biotinylated proteins (upper) or total
protein lysates (lower) was performed using the
indicated antibodies.
(B) MEFs were treated with 25 mM glucose for
15 or 30 min. Cell surface and whole-cell lysate
proteins were visualized as in A using antibodies
for the EGF receptor (EGFR) or transferrin receptor
1 (TFR1).
(C) MEFs were incubated at 20C or 15C for 4 hr
and then treated with 25 mM glucose for 15 or
30 min.
(D) MEFs were pretreated with brefeldin A or
solvent control for 1 hr and then treated with
25 mM glucose for 15 or 30 min in the presence
or absence of brefeldin A. In C and D, cell surface
and whole lysate proteins were visualized as in A.
a decrease in cell size when compared
to cells at 4 mM glucose (Figure 8F).
Reminiscent of the effect of SB431542,
this decrease may reflect the effect of
autocrine TGF-b signaling. However, the
stronger decrease suggests that addi-
tional mediators of cell size may be in-
hibited when silencing MMP-9 expres-
sion. Inhibition of MMP-9 expression did not affect the basal
cell size in endothelial cells and prevented the high glucose-
induced increase in cell size (Figure S3). These results indicate
that MMP-2 andMMP-9 aremediators for glucose-induced acti-
vation of latent TGF-b.
DISCUSSION
Exposure of cells to highglucose has longbeenknown to increase
cell size. We provide evidence for an essential role of autocrine
TGF-b signaling in glucose-induced cell hypertrophy. Glucose-
induced cell hypertrophy required functional TbRI signaling, and
glucose rapidly induced TGF-b signaling, leading to activation of
the Akt-TOR pathway and, consequently, increased cell size.
The TGF-b signaling resulted from a rapid glucose-induced cell
surface presentation of TbRII and TbRI, drastically enhancing the
receptor levels at the cell surface, and a rapid activation of latent
TGF-b by matrix metalloproteinases. These findings have rele-
vance for pathologies associated with high glucose-induced cell
hypertrophy, such as diabetes and cancer, and for the physiology
of cells in culture, in which adding glucose to media is standard.
Glucose-Activated Signaling Leading to Increased
Cell Size
Various extracellular signals induce an increase in protein
synthesis and cell size through activation of the PI3K-Akt-TOR
pathway. Most attention has focused on insulin and growth
factors that act through tyrosine kinase receptors (Hay and
Sonenberg, 2004; Plas and Thompson, 2005). TGF-b family42 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.
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tors. In spite of the different nature of these receptors, TGF-b can
activate PI3K-Akt-TOR-S6 kinase signaling (Lamouille and Der-
ynck, 2007; Das et al., 2008).
Much less is understood about how nutrients, such as amino
acids and glucose, induce increased protein synthesis and cell
size, although exposure of cells to amino acids or high glucose
activates Akt-TOR signaling (Um et al., 2006). How addition of
glucose leads to Akt-TOR signaling has not been well character-
ized, and it has been proposed that changes in intracellular
calcium or indirect activation of Akt by insulin or glucagon-like
peptide GLP-1 may be involved (Holz and Chepurny, 2005).
Conversely, Akt activation causes increased expression and
cell surface localization of the major glucose transporters,
GLUT1 and GLUT4, leading to increased glucose uptake and
glycolysis (Plas and Thompson, 2005).
Role of TGF-b Signaling in Glucose-Induced Cell
Hypertrophy
Central findings are that the glucose-induced increase in cell size
requires functional TGF-b receptors, that glucose induces rapid
B C
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Figure 7. Glucose Increases the Production
of Bioactive TGF-b Ligand
(A) MEFs or NRK-52E cells were treated with
25 mM glucose for 3 hr, and TGF-b1, -b2, and -b3
mRNA were quantified using RT-PCR.
(B) 25 mM glucose was added to MEFs for
different times, and the levels of active TGF-b in
the conditioned media (Cond.) were scored using
the TMLC reporter cells. Media containing no
glucose (glu) or 25 mM glucose (+glu) were
used as controls (Ctl).
(C) 25 mM glucose was added to MEFs for
different times, and the conditioned media were
treated or not with heat prior to the TMLC assay
to measure active TGF-b. Media containing no
glucose or 25 mM glucose, treated with heat,
were used as controls.
(D) 25 mM glucose was added to NRK-52E cells
for 1 hr, and the conditioned media were treated
or not with heat prior to the TMLC assay.
(E) 25 mM glucose was added to MEFs for 1 hr in
the absence or presence of cycloheximide (CHX),
and the conditioned media (Cond.) or glucose-
containing control medium (Ctl) was added to
the TMLC reporter cells. RNA was extracted and
luciferase mRNA was quantified by qRT-PCR.
One out of two experiments is shown with SD for
triplicates.
activation of TGF-b signaling, that
glucose-induced Akt-TOR signaling
depends on the TbRI kinase, and that
adding TGF-b to these cells results in
increased protein synthesis and cell size,
similarly to glucose. These observations
invite the scenario that glucose-induced
cell hypertrophy results from activation
of autocrine TGF-b signaling, leading to
Akt-TOR signaling, or, at a minimum,
that TGF-b signaling through Akt-TOR is
a required component for glucose-induced cell hypertrophy.
Accordingly, both TbRI kinase inhibitor and rapamycin inhibited
high glucose-induced cell hypertrophy. Our results extend
previous findings that linked high glucose to TGF-b. High glucose
was shown, in mesangial cells, to increase expression of extra-
cellular matrix proteins as well as TGF-b (Ziyadeh et al., 1994),
and the increase in collagen synthesis was reduced in the pres-
ence of a neutralizing anti-TGF-b antibody (Sharma et al., 1996;
Ziyadeh et al., 2000). Furthermore, TGF-b1 levels were increased
in the glomerular and tubular kidney compartments in rodent
models of diabetes, and Smad3 activationwas observed in these
cells (Kolm-Litty et al., 1998; Hong et al., 2001; Isono et al., 2002).
Conversely, TGF-b stimulates the expression of the glucose
transporter GLUT1 and glucose uptake in some cell types (Kita-
gawa et al., 1991; Inoki et al., 1999). This finding and our data
that glucose rapidly induces TGF-b signaling together suggest
that glucose-induced TGF-b signaling may provide a positive
feedback mechanism, resulting in increased glucose uptake
and increased glycolysis (Figure 8G).
Finally, our observations that TGF-b induces increased protein
synthesis and cell size in MEFs, NRK-52E cells, and HepG2 cellsDevelopmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 43
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Figure 8. Metalloproteinases Are Essential for Glucose-Induced Activation of TGF-b
(A) MEFs and NRK-52E cells, cultured in 4 mM glucose, were shifted to 4 mM (N) or 25 mM (H) glucose for 30 min in the absence or presence of GM6001. Cells
were assayed by western blotting for phospho-Smad3 (pSmad3) or Smad3.
(B) 25 mM glucose was added to MEFs for 1 hr in the absence or presence of MMP inhibitors as shown. Active TGF-b in the conditioned media and glucose-
containing control medium was scored using TMLC cells.
(C) 25mMglucosewasadded toMEFsorNRK-52Ecells for 15or30min in theabsenceorpresenceofMMP-2orMMP-9 inhibitor, and the levelsof pSmad3andSmad3
were assayed by western blotting.
(D) 25 mM glucose was added to NRK-52E cells for 24 hr in the absence or presence of GM6001. The size distribution of cells in G1 was determined by flow
cytometry.
(E) 25 mM glucose was added for 1 hr to NRK-52E cells transfected with control, MMP-2, or MMP-9 siRNA, and the levels of active TGF-b in the conditioned
media were scored using the TMLC reporter cells.44 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.
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thesecells aswell as endothelial andT4-2carcinomacells extend
our previous finding that TGF-b induces increased protein
synthesis in cells undergoing epithelial-to-mesenchymal transi-
tion (Lamouille and Derynck, 2007). Thus, TGF-b-induced cell
hypertrophy may be a common response in different cell types.
Glucose Rapidly and Selectively Enhances the Cell
Surface Presentation of TGF-b Receptors
The rapid activation of autocrine TGF-b signaling in response to
high glucose appears to result from increased cell surface levels
of TGF-b receptors in combination with activation of TGF-b
made by the cells. The rapid and substantial increases in cell
surface levels of TbRII and TbRI in response to high glucose
strongly enhance the ligand-binding capacity and sensitivity of
the cells to TGF-b. The rapid presentation of TGF-b receptors at
the cell surface was selective, as high glucose did not affect the
cell surface levels of the EGF and transferrin receptors. The
increased TGF-b receptor levels at the cell surface did not result
from increased expression per se, but from increased transport
through the ER and Golgi. Altered receptor recycling may
contribute to the increased cell surface presentation of the TGF-b
receptors. The enhanced cell surface levels of TbRII and TbRI in
cells treated with brefeldin A may result in part from decreased
receptor internalization, since brefeldin A inhibits endocytosis of
certain membrane-bound proteins (Uhlin-Hansen and Yanagish-
ita, 1995). How glucose signals to rapidly and selectively enhance
theTbRII andTbRI levels isaquestion for future research. It isnoted
that increased TbRII expression was observed in glomerular and
tubular kidney cells in diabetic mice (Isono et al., 2000) and that
exposure of podocytes to glucose for 14 days resulted in a 50%
increased TbRII expression (Iglesias-de laCruz et al., 2002). These
effects are long termandmoderate in comparison to the rapid and
drastic increase in cell surface presentation of TbRII and TbRI that
does not correlate with increased receptor expression.
Glucose Induces Rapid Activation of TGF-b Ligand
by Matrix Metalloproteinases
In addition to the rapid increase in TGF-b receptors at the cell
surface, glucose also induced a rapid activation of TGF-b ligand.
Ligand activation is an essential event in the regulation of TGF-b,
especially since the level of active TGF-b is normally minimal,
compared to total TGF-b (Annes et al., 2003). The 10-fold activa-
tion of latent TGF-b within 15 min after adding glucose, to the
extent that a third of all TGF-b is active, is to our knowledge
unprecedented.
MMPs are secreted and cell surface enzymes that process or
degrade various extracellular proteins (Egeblad and Werb,
2002). Several MMPs have been proposed to regulate conver-
sion of latent TGF-b. Among these, enhanced activities of
MMP-2, -9, and/or -13 have been associated with myocardial
or cartilage hypertrophy (Derosa et al., 2007a; D’Angelo et al.,2000), and increased MMP-2 and -9 levels were found in asso-
ciation with diabetes (Derosa et al., 2007b), while high glucose
increased MMP-2 expression (Lee et al., 2007). Our data indi-
cate that the rapid activation of TGF-b in response to high
glucose is mediated by MMPs and that MMP-2 and/or MMP-9
largely account for the activation of TGF-b in response to
glucose. The importance of the MMP-mediated activation of
TGF-b is illustrated by the inhibition of high glucose-induced
hypertrophy of NRK-52E cells by GM6001, or siRNA to MMP-
2 or MMP-9. How glucose signals to activate the MMPs remains
to be determined.
High glucose was shown to induce TGF-b expression, leading
to increased production of extracellular matrix proteins (Ziyadeh
et al., 1994). Accordingly, high glucose induced in NRK-52E cells
a moderate increase in TGF-b mRNAs. Increases in TGF-b
expression confer a long-term response to glucose and cannot
account for the 10-fold activation of TGF-b within 15 min, which
does not require new protein synthesis.
The Glucose-TGF-b Connection in Cell Culture,
Diabetes, and Cancer
Our observations have relevance for the studies of TGF-b in cell
culture. Cells in culture display autocrine TGF-b signaling,
consistent with their expression of TGF-b receptors and
TGF-b1. Since glucose is a standard component of cell culture
media, the cell surface presentation of the TGF-b receptors
and activation of autocrine TGF-b signaling in culture may result
from the addition of glucose. This complements our previous
finding that culturing cells on plastic, i.e., in the absence of extra-
cellular matrix, activates TGF-b1 expression (Streuli et al., 1993).
Finally, glucose enhances the responses to exogenous TGF-b,
consistent with the activation of autocrine TGF-b signaling by
glucose. Accordingly, the TGF-b responses depend on the level
of glucose in the medium.
Our results contribute to the understanding of pathologies in
which increased cell size has been linked to increased glucose
uptake. In diabetes, the prolonged exposure of cells to high
glucose has been linked to hypertrophy of proximal tubular
and mesangial cells, accumulation of extracellular matrix, and
fibrosis, leading to renal insufficiency (Ziyadeh, 2004). Increased
TGF-b expression, in the context of exposure of cells to high
glucose, has also been linked to increased extracellular matrix
production and fibrosis. Our results provide a mechanism of
rapid activation of TGF-b signaling in response to high glucose
and highlight the central role of TGF-b signaling in glucose-
induced cell hypertrophy.
Cancer cells display increased glucose uptake and glycolysis,
when compared to normal cells (Gatenby and Gillies, 2004;
Deberardinis et al., 2008). In fact, the high glucose utilization by
tumors provides the basis for tumor imaging using PET scanning
(Gatenby and Gillies, 2004). Specific oncogenic pathways, such
as those mediated by PI3K or Myc, were shown to regulate(F) NRK-52E cells were transfected with MMP-2, MMP-9, or control siRNA. The size distribution of cells cultured with 4mM or 25mM glucose was determined by
flow cytometry. The gray lines, marked ‘‘Control 4 mM glucose,’’ in the two lower panels correspond to the 4 mM glucose profile in the cells transfected with
control siRNA, shown in the top panel.
(G) Proposed model of the functional interactions of high glucose with TGF-b signaling resulting in increased cell size.
One out of two experiments is shown with SD for triplicates.Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc. 45
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Thompson, 2005; Ruggero and Sonenberg, 2005; Deberardinis
et al., 2008). Therefore, an increase in glucose uptake may
augment cell size and contribute to neoplastic transformation.
Another hallmark of tumor cells is that they show increased
expression and activation of TGF-b, most often TGF-b1 (Derynck
et al., 2001), and often have increased levels and activity of met-
alloproteinases, in particular MMP-2 and MMP-9 (Egeblad and
Werb, 2002). Based on our results, it is tempting to link increased
glucose uptake by tumor cells to increased MMP-2 and MMP-9
activity, leading to activation of TGF-b. This scenario would
connect increased glucose uptake with increased TGF-b activity
and increased cell size in the context of cancer progression.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
Wild-type and TbRI/ mouse embryonic fibroblasts (MEFs) (Larsson et al.,
2001) were provided by S. Karlsson (Lund University Hospital, Sweden) and
spontaneously immortalized. MEFs from Smad3/ mice and wild-type litter-
mates (Datto et al., 1999) were obtained from X.-F. Wang (Duke University
Medical School). The MEFs were propagated in DMEM with glucose (4.5 g/l)
and 10% fetal bovine serum (FBS). NRK-52E cells were cultured in DMEM
with glucose (4.5 g/l) and 5% bovine calf serum (BCS). Human T4-2 breast
carcinoma cells were obtained from M.J. Bissell (Lawrence Berkeley National
Lab) and cultured on collagen (PureCol, Inamed Biomaterials) in 50:50 mix of
DMEM and F12 medium supplemented with 5 mg/ml prolactin, 250 ng/ml
insulin, 1.4 3 106 M hydrocortisone, 1010 M b-estradiol, 2.6 ng/ml sodium
selenite, and 10 mg/ml transferrin. Human umbilical vein endothelial cells
(HUVECs) were obtained from Cascade Biologics and propagated in Medium
200 and low Serum Growth Supplement (LSGS) (Cascade Biologics). Human
HepG2 hepatocellular carcinoma cells were from ATCC and cultured in DMEM
with glucose (4.5 g/l) and 10% fetal bovine serum (FBS).
Effects of Glucose or TGF-b in Cell Culture
To study the effect of glucose, cells were cultured in medium without glucose
or with 4 mM D-glucose for 24 hr and then switched to medium with 25 mM
glucose for 15 min to 24 hr. To study the reversibility of the effect of glucose,
the NRK-52E cells that were cultured in medium with 25 mM glucose for 24 hr
were washedwith PBS and then incubated with DMEMwithout glucose or with
4 mM glucose for 48 hr. For osmolarity control, NRK-52E cells were treated
with 25 mM D-mannose (Sigma-Aldrich) for 24 hr. To study the effect of
TGF-b, cells were treated with 1 to 10 ng/ml TGF-b1 (PeproTech) for 15 min
to 24 hr. To inhibit the TbRI kinase or TOR activity, 3 mM SB431542 (Sigma-Al-
drich) or 100 nM rapamycin (Calbiochem) was added 1 hr before the switch to
high glucose and during treatment. The solvent DMSO was used as a control
for both inhibitors.
Flow Cytometry
Cells were trypsinized and resuspended in PBS containing 2% FBS and
incubated with 7 mg/ml Hoechst 33342 (Sigma-Aldrich) for 45 min at room
temperature. 1 mg/ml propidium iodide (Sigma-Aldrich) was added prior to
flow cytometry, performed using a sorter/analyzer SE three-laser system
(FACSVantage; Becton Dickinson). The cell cycle and cell size were analyzed
using Flowjo software (Tree Star Inc.).
Protein Content and New Protein Synthesis Assays
To measure protein content, cells were trypsinized, and the cell number was
determined. The cells were lysed in radioimmunoprecipitation assay buffer
with protease inhibitors, and the protein content was quantified using protein
assay (Bio-Rad Laboratories) and normalized to cell number. To quantify new
protein synthesis, cells were incubated in leucine-free DMEM overnight, and
5 mCi/ml 3H-leucine (Perkin Elmer) was added for 3 hr. 3H-leucine incorporation
was quantified as described (Franch et al., 1995) using a scintillation counter
(LS 3801; Beckman) and normalized against cell number. Unless stated other-
wise, all graphs show one out of two experiments, with SD for triplicates.46 Developmental Cell 17, 35–48, July 21, 2009 ª2009 Elsevier Inc.RNA Interference
The mouse TbRI siRNA (Mm_Tgfbr1_4), rat MMP-2 siRNA (Rn_Mmp2_1_HP),
rat MMP-9 siRNA (Rn_RGD:621320_1_HP), human MMP-2 siRNA
(Hs_MMP2_5), human MMP-9 siRNA (Hs_MMP9_5), and control siRNA were
from QIAGEN. Transfections of siRNA were performed using Lipofectamine
RNAiMAX (Invitrogen). To study the effect of TbRI, cells were cotransfected
with green fluorescent control siRNA (QIAGEN, Neg. siRNA AF 488) and
TbRI siRNA or control siRNA at a 1:9 ratio followed by indicated assays. To
study the effect of MMP-2 or -9, cells were transfected with siRNA for rat or
human MMP-2 or MMP-9.
Transfections and Luciferase Assays
MEFs and NRK-52E cells were starved overnight in serum-free, glucose-
depleted DMEM. Transfections, TGF-b treatments, and reporter assays
were done as described (Alliston et al., 2005). The total amount of transfected
DNA was kept constant by adding control vector DNA as needed. 24 hr after
transfection, cells were treated with 2 ng/ml TGF-b in the presence or absence
of 25 mM glucose for 12–24 hr, and luciferase activities were measured.
Results are shown as luciferase expression values normalized for transfection
efficiency.
Immunofluorescence Microscopy
Cells were fixed with 4% PFA for 30 min, permeabilized in 2% PFA and 0.2%
Triton X-100 for 10 min, and incubated in PBS - 3% BSA blocking solution for
1 hr. The slides were incubated for 2 hr with anti-Smad2/3 (BD Biosciences),
diluted (1:500) in PBS - 3% BSA, and stained for 1 hr with FITC-conjugated
secondary antibody (1:500; Invitrogen). Slides were incubated with DAPI
(1:10,000; Sigma-Aldrich) for 10 min to stain the nuclei. Cells were viewed by
epifluorescence microscopy.
Cell Surface Biotinylation
Cells were washed with ice-cold PBS and incubated with EZ-link Sulfo-NHS-
LC-Biotin (0.5 mg/ml in PBS). Biotinylation reactions were stopped using 0.1M
glycine in PBS, and cells were lysed in MLB lysis buffer (20 mM Tris-Cl,
200 mM NaCl, 10 mM NaF, 1 mM NaV2O4, 1% NP-40, 2 mM Pefabloc,
0.5 mM Leupeptin, and 1 g/ml Aprotinin [pH 7.5]). Cell lysates were incubated
overnight with Neutravidin beads (Pierce), and the beads were then washed
three times with MLB lysis buffer. The adsorbed proteins were analyzed by
SDS-PAGE and western blot using anti-TbRI (V-22) (Santa Cruz), anti-TbRII
(L-21) (Santa Cruz), anti-EGFR (1005) (Santa Cruz), or anti-TfR1 (13-6800)
(Invitrogen) antibodies. These antibodies and anti-a-tubulin antibody (Sigma)
were also used in parallel western blot assays of total lysates.
Immunoblotting for TGF-b Signaling
To evaluate the activation of TGF-b signaling, cells were washed with PBS and
lysed as described above. The total cell proteins were analyzed by SDS-PAGE
and western blot using anti-Smad2/3 (#3102), anti-Smad3 (C67H9) (#9523),
anti-pSmad3 (Ser423/425) (C25A9) (#9520), anti-pAkt (Ser473) (#9271), or
anti-Akt (#9272) from Cell Signaling Technology. The anti-a-tubulin antibody
(Sigma) was used as a loading control.
RNA Preparation and Quantitative Real-Time PCR
RNA was prepared using the RNeasy mini-kit (QIAGEN). Reverse transcrip-
tions were performed using M-MLV reverse transcriptase and random hex-
amer oligodeoxynucleotides (Invitrogen). Real-time PCR was performed with
SYBRGreen I Dye (Molecular Probes) and the following primers: Smad7, 50-TG
CTGTGAATCTTACGGGAAG-30 and 50-AATCCATCGGGGTATCTGGAG-30;
Firefly luciferase, 50-GCTGGGCGTTAATCAGAGAG-30 and 50-GTGTTCGTCTT
CGTCCCAGT-30. Ribosomal protein L19 (rPL19) was used as internal control.
The primers for rPL19 were 50-ATGTATCACAGCCTGTACCTG-30 and 50-TTC
TTGGTCTCTTCCTCCTTG-30.
Temperature Blockade
MEFs were starved overnight in DMEM without glucose (Invitrogen) at 37C
and 5% CO2. For 20
C or 15C block, the medium was replaced with 2–8C
glucose-depleted DMEM buffered with 10 mM HEPES, and cells were incu-
bated at 20C or 15C for 4 hr. Release of the blockade was started by
Developmental Cell
Glucose Increases Cell Size through TGF-b Signalingreplacing HEPES-buffered DMEMwith 37Cmediumwithout HEPES (Milgram
and Mains, 1994; Saraste et al., 1986).
TGF-b Bioassay
Active TGF-b was measured using TMLC reporter cells (Abe et al., 1994)
provided by D.B. Rifkin (New York University School of Medicine). MEFs or
NRK-52E cells were starved with serum-free, glucose-depleted DMEM over-
night and stimulated with 25 mM glucose for 15 min to 1 hr or left untreated.
As needed, MMP inhibitors GM6001, MMP-2 inhibitor I, MMP-9 inhibitor I,
MMP-2/MMP-9 inhibitor III, or CL-82198 (Calbiochem, CA) was added 1 hr
before and then during glucose treatment. DMSO solvent was used as
a control. Conditioned media were heated at 80C for 10 min or kept at 4C
until assayed. TMLC cells were treated with conditioned medium or serial dilu-
tions of a TGF-b standard for 12–24 hr. Glucose-depleted DMEM or DMEM
with 25 mM glucose was used as a control, and assay values were derived
as described (Abe et al., 1994). To increase the concentration of TGF-b, the
conditioned media from NRK-52E cells were concentrated using Microcon
centrifugal filters (Millipore).
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